Age-related brain structural alterations as an intermediate phenotype of psychosis

Juergen Dukart, PhD; Renata Smieskova, PhD; Fabienne Harrisberger, PhD; Claudia Lenz, PhD; Andre Schmidt, PhD; Anna Walter, MD; Christian Huber, MD; Anita Riecher-Rossler, MD, PhD; Andor Simon, MD; Undine E. Lang, MD, PhD; Paolo Fusar-Poli, MD, PhD; Stefan Borgwardt, MD, PhD

Introduction

Neuroanatomical studies and meta-analyses in patients with schizophrenia and patients with first-episode psychosis (FEP) have consistently reported evidence of brain structural abnormalities, as measured by structural MRI (sMRI).1–11 Structural alterations commonly found in these studies are volumetric alterations in the anterior cingulate, frontal and temporal regions; hippocampus; amygdala; thalamus; and insula.2,8,12–15 Decreases, increases and negative findings were found, with most studies reporting reduced total and regional grey matter volumes. A comprehensive meta-analysis of these studies indicated the progressive nature of most of these brain structural alterations.3 Additionally, a recent meta-analysis of longitudinal studies found a correlation of these longitudinal brain structural alterations with exposure to antipsychotic treatment, but not with illness duration.16 In contrast, a large cross-sectional meta-analysis found correlations with both factors.17 Another study suggested abnormal nonlinear growth processes as a contributing factor for the observed longitudinal structural alterations.18 Overall, the findings on the directions and location of structural alterations are highly heterogeneous, even across the meta-analyses. It remains largely unclear if and which of the reported structural alterations are linked to specific clinical symptoms and represent an early biomarker or a consequence of psychosis.

A possible way to resolve this question on the time of occurrence of structural alterations in patients with schizophrenia is by examining individuals with a high risk for psychosis (i.e., at-risk mental state, ARMS).19–21 If alterations reported in patients with FEP are a cause or at least a phenotype unrelated to early diagnosis and treatment, one would expect to find similar alterations, though probably less expressed, in the ARMS population. Recent studies aimed to answer this
question by comparing individuals with ARMS to healthy controls or patients with FEP. Only a subset of those studies compared volumetric information among individuals with ARMS, patients with FEP and healthy controls using unbiased whole-brain approaches. Although most of these studies reported prefrontal and temporal decreases in individuals with ARMS compared with healthy controls, the largest study so far failed to find any structural differences among the groups. None of the identified studies tested for age-related differences in the identified brain structural alterations among the groups, and only 1 evaluated the link between structural changes found in individuals with ARMS and observed clinical symptoms with a primary focus on cognitive deficits. In particular, understanding the associations between observed structural endophenotypes and specific symptoms is essential to establish their relevance as potential treatment biomarkers. Possible reasons for the inconsistent findings with respect to brain structural alterations may include differences in sample sizes, control populations, preprocessing and statistical methodology, demographic factors, or the known heterogeneity of psychotic populations. Correspondingly, from these studies it remains unclear if brain structural alterations in individuals with ARMS can be considered a consequence or an intermediate or predisposing phenotype on the way to manifested psychosis. It also remains unknown whether these structural alterations evolve with age and how they are linked to specific clinical symptoms.

Here we aim to address these questions of early psychosis-related structural brain alterations and their association with age and psychotic symptoms by comparing different structural measures among individuals with ARMS, healthy controls and patients with FEP. We further evaluate if structural alterations observed in patients with FEP and individuals with ARMS are differentially modified by age as compared with each other and with healthy controls. Presence of such interactions between diagnostic groups and age would suggest a differential evolution of brain structural measures over time or different underlying structural pathology in younger and older patients with FEP and individuals with ARMS that might explain the heterogeneity of previous literature findings. Finally, to understand the relevance of the identified structural alterations for specific symptoms we evaluate in subsequent exploratory analyses if the identified brain structural phenotypes are linked to specific psychiatric symptoms observed in those populations.

Individuals with ARMS and patients with FEP had been seeking help and were assigned to the FePsy study. They were examined by a trained psychiatrist; among other examinations and upon their agreement, MRI scans were obtained as part of the evaluation. Each patient had a case manager who treated them for the duration of the study and who decided if they were able to participate in subsequent examinations, especially if the examinations were not therapeutically relevant (e.g., research sMRI). Participants’ inclusion into the present MRI examination occurred between November 2008 and April 2014. Among the patients who were considered suitable to undergo MRI and who agreed to participate, some were excluded because of medical conditions (acute psychotic symptoms, anxiety and tinnitus), and some decided immediately before the scan not to participate. Before the sMRI section each participant was informed in detail about the procedure and its possible risks and benefits.

The FEP group fulfilled the operational criteria for FEP as described by Yung and colleagues, but not the criteria for schizophrenia. Inclusion in the FEP group required scores above 3 on the hallucination item or scores above 4 on the unusual thought content, suspiciousness or conceptual disorganization items of the Brief Psychiatric Rating Scale (BPRS). The BPRS was administered on average 9 ± 16 days before or after the MRI examination. In addition, the Scale for Assessment of Negative Symptoms (SANS) was administered in a subsample of participants. The symptoms must have occurred at least several times a week and persisted for more than 1 week.

The ARMS group was defined based on Personal Assessment and Crisis Evaluation (PACE) criteria used in previous MRI studies. The very good interrater and prognostic reliability of these criteria have been established in our previous studies. Inclusion thus required 1 or more of the following: attenuated psychotic symptoms, brief limited intermittent psychotic symptoms (BLIPS), or a first-degree relative with a psychotic disorder plus at least 2 indicators of a clinical change, such as a marked decline in social or occupational functioning. Inclusion because of attenuated psychotic symptoms required scores of 2 or 3 on the hallucination item and scores of 3 or 4 on the unusual thought content or suspiciousness items of the BPRS for at least several times a week and persisting for more than 1 week. Inclusion because of BLIPS required scores of 4 or higher on the hallucination item, or 5 or higher on the unusual thought content, suspiciousness or conceptual disorganization items of the BPRS, with each symptom lasting less than 1 week before resolving spontaneously.

Healthy controls were recruited through local advertisement. To be included, they had to have no history of psychiatric illness, head trauma, neurologic illness, serious medical or surgical illness, or substance dependence, and no family history of any psychiatric disorder, as assessed by an experienced psychiatrist in a detailed clinical interview.

Exclusion criteria for all groups were age younger than 18 years, insufficient knowledge of German, IQ below 70, previous episode of schizophrenic psychosis (treated with major tranquilizers for more than 3 weeks), psychosis due to organic

Methods

Participants

We recruited patients with FEP, individuals with ARMS and healthy controls in the framework of the Basel FePsy study (Früherkennung von Psychosen). All participants provided written informed consent and received compensation for participating in the present study. The study was approved by the local ethics committee (Ethikkommission Nordwest-und Zentralschweiz [EKNZ]).
Brain structural alterations as a phenotype of psychosis

Reasons or substance dependence, psychotic symptoms within a clearly diagnosed affective psychosis, or borderline personality disorder.

**Structural MRI**

All participants were scanned using a Siemens (Erlangen, Germany) MAGNETOM Verio 3 T scanner with a 12-channel radiofrequency head coil. Head movement was minimized by foam padding across the forehead. A whole-brain 3-dimensional $T_1$-weighted magnetization prepared rapid acquisition gradient (MPRAGE) sequence was applied. The acquisition was based on a sagittal matrix of 256 x 256 x 176 and 1 x 1 x 1 mm$^3$ isotropic spatial resolution, with an inversion time of 1000 ms, repetition time of 2 s, echo time of 3.4 ms, flip angle of $8^\circ$ and bandwidth of 200Hz/pixel. All images were reviewed by trained neuroradiologists and assessed for radiological abnormalities.

**Image preprocessing**

All image preprocessing and subsequent statistical analyses of imaging data were performed using Statistical Parametric Mapping software version 12 (SPM12) implemented in Matlab R2013a. Image preprocessing comprised segmentation and spatial normalization of sMRI data into Montreal Neurological Institute (MNI) space using NewSegment and modulation of the normalized grey matter probability maps using the Jacobian determinants to preserve the total amount of signal (these maps are commonly referred to as voxel-wise grey matter volume). Further, we computed for each participant voxel-based cortical thickness (VBCT) maps using the VBCT toolbox provided for SPM12. In brief, the VBCT algorithm assigns to each grey matter voxel a value corresponding to its Euclidean distance to the white matter and cerebrospinal fluid boundary. The VBCT maps were spatially normalized into MNI space using parameters obtained from NewSegment. Both grey matter volume and VBCT maps were smoothed with an 8 mm full-width at half-maximum Gaussian kernel.

**Statistical analysis**

We compared the clinical and demographic characteristics among the 3 groups using analyses of variance (ANOVA) and $\chi^2$ tests (where appropriate), as implemented in SPSS software version 22. We considered results to be significant at $p < 0.05$. In case of significant between-group differences in an ANOVA, we performed post hoc Bonferroni-corrected $t$ tests.

**Imaging data**

Voxel-wise general linear model analyses were computed for both grey matter volume and VBCT maps, including group (FEP, ARMS, control) as a factor and covarying for sex, education and total intracranial volume. Grey matter alterations in the age range covered in our cohort have been shown to be sufficiently approximated by a cubic function. Correspondingly, a cubic age regressor was further included in the voxel-wise general linear model analyses. Further, as we were specifically interested in potential differences in age-related alterations, the cubic age regressor was modeled as an interaction term with the diagnosis. We also explored the option of using a linear age term. However, the results did not differ as compared with the cubic model. For both grey matter volume and VBCT we tested for 12 different $t$ contrasts looking for regional relative volumetric between-group differences and for differences in age slopes in the pairwise comparisons of ARMS, FEP and control groups (6 contrasts [control > FEP, control < FEP, control > ARMS, control < ARMS, FEP > ARMS and FEP < ARMS] testing for increases or decreases in pairwise group comparisons, and 6 respective contrasts testing for age x group interactions).

As we were interested in identifying all regions associated with group differences and group-specific age-related alterations rather than peak voxels showing the maximum effects, to evaluate their association with clinical symptoms we used a whole-brain family-wise-error (FWE)-corrected cluster threshold of $p < 0.05$ adjusted for nonstationarity of smoothness combined with a voxel-wise uncorrected threshold of $p < 0.05$. For grey matter volume analyses the cluster threshold $p$ values were determined using the nonstationarity correction suggested for this modality. For VBCT analyses, we determined an exact whole-brain corrected cluster threshold of $p < 0.05$ using permutation statistics (1000 permutations), as implemented in the AlphaSim function. Importantly, as the main purpose of the study was to evaluate the link of structural alterations to clinical symptoms observed in the FEP and ARMS groups, a liberal voxel-wise threshold combined with a whole-brain corrected cluster-wise threshold was chosen to ensure that potentially smaller but more widespread effects were captured for subsequent correlations with clinical symptoms within the clinical groups. Further, to visualize the identified significant associations, we used grey matter volume or VBCT eigenvariates extracted from the significant clusters with the highest respective $t$ values identified in the corresponding contrasts. Eigenvariates obtained from clusters showing differences in direct comparisons between groups were adjusted for all covariates of no interest (age, sex, education and total intracranial volume [TIV]). Eigenvariates extracted from clusters showing significant group x age interactions were adjusted for all covariates of no interest for these contrasts (sex, education and TIV, but not age). The adjusted eigenvariates from regions showing group x age interactions were plotted as a cubic function of age with the corresponding confidence intervals (CIs) separately for each group. Additionally, to provide an estimate of the magnitude of the structural alterations and their similarity between the FEP and ARMS groups, we computed effect sizes (Cohen $d$) for both ARMS and FEP relative to healthy controls based on cluster eigenvariates from contrasts testing for between-group differences.

**Correlations between imaging and clinical measures**

To evaluate whether any of the identified structural alterations were associated with psychopathological symptoms observed in patients with FEP or individuals with ARMS we...
performed an exploratory analysis computing Pearson correlation coefficients between BPRS subscales and extracted eigenvariates. An excellent interrater and a fair longitudinal reliability have been established for the BPRS in previous studies.43,44 Correlations were computed within each group between the extracted eigenvariates from the most significant clusters identified in each contrast (adjusted for covariates of no interest) and clinical symptoms, as measured with the BPRS total scores and its 6 subcomponent (mood disturbance, reality disturbance, activation, apathy, disorganization and somatization) scores.45 Only the patients for whom BPRS scores were available were included in all correlations analyses. All findings from these exploratory correlational analyses are reported at a significance level of p < 0.01. Further, to test if the evaluated BPRS subcomponents or the total score were associated with age, we computed Pearson correlations using a threshold of p < 0.05, uncorrected. To rule out that the identified significant correlations between structural alterations and BPRS subscale scores in the FEP or ARMS groups were confounded by medication status, we additionally computed partial correlations controlling for antipsychotic and antidepressant medication status. Both were entered into these partial correlation analyses as binary (yes/no) variables.

**Results**

**Participants**

Of the FePsy participants who were deemed suitable to undergo MRI and who agreed to participate in the present study, 5 (4 individuals with ARMS, 1 patient with FEP) were excluded because of medical conditions, such as acute psychotic symptoms, anxiety and tinnitus, and 4 withdrew immediately before the scan. Additionally, we excluded 5 controls because of medical conditions (incidental findings), resulting in a final sample of 59 patients with FEP, 59 with ARMS and 26 healthy controls with available sMRI scans.

**Clinical and demographic findings**

The demographic and clinical characteristics of participants are shown in Table 1. The groups did not differ in terms of age or age range. We observed significant between-group differences with respect to sex, education, and alcohol and cannabis consumption. Healthy controls were more often female, they had a higher level of education than patients with FEP (t\(_{83} = 3.0, p = 0.004\)) and individuals with ARMS (t\(_{83} = 2.6,\ p = 0.011\)), and they had a greater prevalence of moderate alcohol consumption and a lower prevalence of cannabis consumption than either of the patient groups. Correspondingly, sex and education were included as covariates of no interest in all imaging analyses.

**Voxel-based morphometry**

In voxel-wise grey matter volume group comparisons, we found significantly higher grey matter volume in patients with FEP and those with ARMS than in healthy controls in an extensive network covering the left prefrontal temporal, insular, right precuneus and bilateral parietal regions in patients with FEP and the right prefrontal, temporal, parietal, ventral striatal and bilateral precuneus regions in those with ARMS (Fig. 1A, Table 2). No differences in grey matter volume were observed between patients with FEP and those with ARMS. Effect sizes for the differences between healthy controls and either patients with FEP or those with ARMS ranged from 0.7 to 0.92, indicating strong effects (Fig. 1A), and were in general comparable for both the FEP and ARMS groups for all significant clusters. Significantly higher age-related reductions of grey matter volume were found in both patients with FEP and those with ARMS than in healthy controls (Fig. 2A, Table 2). In individuals with ARMS significantly stronger age-related grey matter volume decreases were observed in the bilateral subgenual, ventral striatal, insular and premotor regions. A similar but more widespread network of stronger age-related decline compared with healthy controls was also observed in patients with FEP, covering bilateral dorsolateral

---

**Table 1: Characteristics of the study sample**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Control (n = 26)</th>
<th>ARMS (n = 59)</th>
<th>FEP (n = 59)</th>
<th>Statistical test</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex, male:female</td>
<td>12:14</td>
<td>43:16</td>
<td>42:17</td>
<td>( \chi^2 = 6.5 )</td>
<td>0.038</td>
</tr>
<tr>
<td>Age, yr [range]</td>
<td>27.7 ± 4.5 [20–39]</td>
<td>24.7 ± 5.7 [18–43]</td>
<td>26.4 ± 6.7 [18–42]</td>
<td>( F_r = 2.7 )</td>
<td>0.07</td>
</tr>
<tr>
<td>Education, yr</td>
<td>15.6 ± 3.1</td>
<td>13.8 ± 2.9</td>
<td>13.4 ± 3.1</td>
<td>( F_r = 4.8 )</td>
<td>0.009</td>
</tr>
<tr>
<td>BPRS score (n)</td>
<td>24.5 ± 1.1 (25)</td>
<td>39.4 ± 8.6 (49)</td>
<td>49.7 ± 14.5 (47)</td>
<td>( \chi^2 = 46.3 )</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>SANS (n)</td>
<td>0 ± 0 (17)</td>
<td>11.0 ± 11.9 (19)</td>
<td>18.0 ± 14.8 (21)</td>
<td>( \chi^2 = 11.8 )</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>On antipsychotics, no.</td>
<td>0</td>
<td>0</td>
<td>28†</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>On antidepressants, no.</td>
<td>0</td>
<td>23</td>
<td>12</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Cannabis use, %</td>
<td>15.4</td>
<td>28.1</td>
<td>23.9</td>
<td>( \chi^2 = 1.6 )</td>
<td>0.45</td>
</tr>
<tr>
<td>Smoking, %</td>
<td>26.9</td>
<td>51.7</td>
<td>59.3</td>
<td>( \chi^2 = 7.6 )</td>
<td>0.022</td>
</tr>
<tr>
<td>Alcohol consumption, %, no:moderate:uncontrolled</td>
<td>4:89:8</td>
<td>21:66:14</td>
<td>34:54:12</td>
<td>( \chi^2 = 11.1 )</td>
<td>0.025</td>
</tr>
</tbody>
</table>

ARMS = at-risk mental state; BPRS = Brief Psychiatric Rating Scale; FEP = first-episode psychosis; SANS = Scale for Assessment of Negative Symptoms; SD = standard deviation.

†Antipsychotic medications were aripiprazole (n = 4), quetiapine (n = 11), paliperidone (n = 2), olanzapine (n = 7), risperidone (n = 3) and clozapine (n = 1). The mean chlorpromazine equivalent was 216 ± 267 mg.
Fig. 1: Voxel-based morphometry group comparisons. (A) Regions showing increased grey matter volume in individuals in an at-risk mental state (ARMS) and in patients with first-episode psychosis (FEP) compared with healthy controls. Combined bar and scatter plots show the grey matter volumes (cluster eigenvariates) for the 3 groups in the depicted clusters. The outline colour of the plots corresponds to the colour of the significant clusters for the corresponding contrast. Error bars represent 95% confidence intervals. (B) Correlations in the FEP group between eigenvariates extracted from significant clusters identified in group comparisons and subcomponents of the Brief Psychiatric Rating Scale (BPRS). Correlation with the eigenvariates of the cluster identified in the contrast control < ARMS is outlined in red. Correlations with the eigenvariates of the cluster identified in the contrast control < FEP are outlined in blue.
prefrontal, premotor, motor and right temporal regions. Parts of this network covering bilateral premotor and motor but also other regions, including the precuneus and superior temporal regions, showed a significantly faster age-related grey matter volume decline in patients with FEP than in those with ARMS.

Table 2: Regions showing significant differences in group comparisons and interactions with age

<table>
<thead>
<tr>
<th>Modality</th>
<th>Contrast</th>
<th>CI</th>
<th>Anatomic regions</th>
<th>Cluster size</th>
<th>p value</th>
<th>Peak t value</th>
<th>Peak MNI coordinate (x, y, z)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grey matter volume</td>
<td>ARMS &gt; control</td>
<td>1</td>
<td>Right superior, middle and inferior frontal gyrus, temporal pole, superior, middle and inferior temporal gyrus, operculum, anterior insula, putamen, transverse temporal gyrus, triangular gyrus, posterior insula, supramarginal gyrus, pallidum</td>
<td>14 165</td>
<td>0.001</td>
<td>3.637</td>
<td>62, –26, –15</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2</td>
<td>Right superior parietal lobe, angular gyrus, postcentral gyrus, cuneus and supramarginal gyrus, bilateral precuneus, posterior cingulate cortex</td>
<td>5427</td>
<td>0.035</td>
<td>3.306</td>
<td>39, –68, 45</td>
</tr>
<tr>
<td>Grey matter volume</td>
<td>FEP &gt; control</td>
<td>1</td>
<td>Left postcentral gyrus, supramarginal gyrus, angular gyrus, superior parietal lobe, operculum, precentral gyrus, planum temporale, superior and middle temporal gyrus, posterior insula</td>
<td>8403</td>
<td>0.002</td>
<td>3.745</td>
<td>–60, –33, 21</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2</td>
<td>Right superior parietal lobe, supplementary motor cortex, postcentral gyrus, cuneus, superior occipital gyrus, bilateral precuneus, supplementary motor cortex, precentral gyrus, left and middle frontal gyrus</td>
<td>9256</td>
<td>0.005</td>
<td>3.316</td>
<td>11, –2, 54</td>
</tr>
<tr>
<td>Grey matter volume</td>
<td>Age interaction: control &gt; ARMS</td>
<td>1</td>
<td>Bilateral supplementary motor cortex, superior and middle frontal gyrus, precentral gyrus, right triangular gyrus, operculum, inferior frontal gyrus</td>
<td>6375</td>
<td>0.016</td>
<td>3.751</td>
<td>50, 18, 33</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2</td>
<td>Bilateral rectal gyrus, medial frontal cortex, insula, putamen, accumbens, caudate nucleus, basal forebrain, anterior cingulate cortex, thalamus, subcallosal area, right medial orbital gyrus, superior medial frontal gyrus</td>
<td>8522</td>
<td>0.044</td>
<td>3.671</td>
<td>6, 8, –21</td>
</tr>
<tr>
<td>Grey matter volume</td>
<td>Age interaction: control &gt; FEP</td>
<td>1</td>
<td>Bilateral superior and middle frontal gyrus, precentral gyrus, triangual gyrus, pre- and postcentral gyrus, operculum, insula, orbitofrontal cortex, left superior, middle and inferior temporal gyrus, temporal pole,</td>
<td>26 513</td>
<td>&lt; 0.001</td>
<td>4.452</td>
<td>33, 12, 38</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2</td>
<td>Left pre- and postcentral gyrus, superior and middle frontal gyrus, operculum, superior parietal lobe</td>
<td>6459</td>
<td>0.014</td>
<td>3.75</td>
<td>–36, –20, 62</td>
</tr>
<tr>
<td>Grey matter volume</td>
<td>Age interaction: ARMS &gt; FEP</td>
<td>1</td>
<td>Right pre- and postcentral gyrus, supramarginal gyrus, superior parietal lobe, operculum, planum temporale, insula, bilateral posterior cingulate gyrus, cuneus, left superior occipital gyrus, calcarine cortex</td>
<td>12 555</td>
<td>0.002</td>
<td>3.653</td>
<td>–5, –47, 26</td>
</tr>
<tr>
<td>VBCT</td>
<td>Control &gt; ARMS</td>
<td>1</td>
<td>Bilateral superior and middle frontal and precentral gyrus</td>
<td>6191</td>
<td>0.009</td>
<td>3.62</td>
<td>11, –11, 77</td>
</tr>
<tr>
<td>VBCT</td>
<td>ARMS &gt; control</td>
<td>1</td>
<td>Bilateral superior parietal lobe, left inferior occipital gyrus, superior parietal lobe, angular gyrus, middle occipital gyrus, occipital pole, cerebellum exterior</td>
<td>11 365</td>
<td>&lt; 0.001</td>
<td>3.85</td>
<td>–17, –95, 11</td>
</tr>
<tr>
<td>VBCT</td>
<td>FEP &gt; control</td>
<td>1</td>
<td>Left superior, middle and inferior occipital gyrus, operculum, fusiform gyrus, cerebellum exterior</td>
<td>5574</td>
<td>0.017</td>
<td>4.78</td>
<td>–17, –96, 5</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2</td>
<td>Right superior, middle and inferior occipital gyrus, occipital pole, cerebellum exterior, fusiform and lingual gyrus, calcarine cortex</td>
<td>5493</td>
<td>0.020</td>
<td>4.53</td>
<td>23, –96, 5</td>
</tr>
<tr>
<td>VBCT</td>
<td>Age interaction: Control &gt; ARMS</td>
<td>1</td>
<td>Left cerebellum exterior, fusiform gyrus, superior, middle and inferior temporal gyrus, angular gyrus, inferior and middle occipital gyrus, parahippocampal gyrus, lingual gyrus hippocampus</td>
<td>8959</td>
<td>&lt; 0.001</td>
<td>4.25</td>
<td>–54, –53, 6</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2</td>
<td>Left superior and middle frontal gyrus, frontal pole, triangular gyrus, bilateral medial prefrontal gyrus, anterior cingulate gyrus</td>
<td>10 262</td>
<td>&lt; 0.001</td>
<td>3.98</td>
<td>–2, 42, 18</td>
</tr>
<tr>
<td></td>
<td></td>
<td>3</td>
<td>Right superior, middle and inferior temporal gyrus, inferior and middle occipital gyrus, cerebellum exterior, fusiform gyrus</td>
<td>5626</td>
<td>0.017</td>
<td>3.53</td>
<td>41, –71, –27</td>
</tr>
<tr>
<td></td>
<td></td>
<td>4</td>
<td>Bilateral precuneus, posterior cingulate gyrus, lingual gyrus, vermis, cerebellum exterior, cuneus, lingual gyrus, calcarine cortex</td>
<td>8066</td>
<td>&lt; 0.001</td>
<td>3.15</td>
<td>0, –54, 51</td>
</tr>
<tr>
<td>VBCT</td>
<td>Age interaction: control &gt; FEP</td>
<td>1</td>
<td>Bilateral cerebellum exterior, lingual gyrus, vermis, fusiform gyrus, left parahippocampal gyrus</td>
<td>5467</td>
<td>0.020</td>
<td>3.74</td>
<td>12, –45, –23</td>
</tr>
</tbody>
</table>

ARMS = at-risk mental state; CI = cluster number; FEP = first-episode psychosis; MNI = Montreal Neurological Institute; VBCT = voxel-based cortical thickness.
Voxel-based cortical thickness

When comparing VBCT across the 3 groups, we found significant increases in both patients with FEP and those with ARMS compared with healthy controls (Fig. 3, Table 2). In both patients with FEP and those with ARMS these increases were observed in bilateral occipital regions. In the ARMS group the significant clusters additionally extended to bilateral parietal cortices. Furthermore, we observed significantly lower VBCT in individuals with ARMS than in healthy controls in bilateral premotor and motor cortices. No significant differences were observed in VBCT between the FEP and ARMS group. The VBCT differences between healthy controls and either patients with FEP or those with ARMS were slightly lower than the VBM differences, ranging from 0.59 to 0.83 (Fig. 1A), and were comparable for both the FEP and ARMS groups for all significant clusters (Fig. 3). In both patients with FEP and those with ARMS we identified significantly higher age-related cortical thinning than in healthy controls (Fig. 4A, Table 2). In the ARMS group these differences covered an extensive network, including bilateral dorsolateral prefrontal, anterior cingulate, inferior parietal, fusiform, posterior middle and inferior temporal, cerebellar and precuneal regions. In the FEP group the significant differences were more...
focal, covering bilateral cerebellar and fusiform regions. No differences with respect to age-related cortical alterations were observed in the direct comparisons between the FEP and ARMS groups.

Correlations between imaging and clinical measures

None of the BPRS subcomponent scores or the total BPRS score correlated with age (all $p > 0.10$). In the ARMS group,
the only significant positive correlation with BPRS total score was found with VBCT in occipital regions (obtained from the group comparison contrast FEP > control; Fig. 3A). In the FEP group, significant negative correlations were found between grey matter volume from the group comparison contrast FEP > control and BPRS total score, and BPRS activation and disorganization subcomponent scores (Fig. 1B). Furthermore, significant negative correlations were found in patients with FEP between the BPRS activation subcomponent score and prefrontal and parietal grey matter volume from the group comparison contrast ARMS > control and prefrontal grey matter volume from the age interaction contrast ARMS < control and FEP < control (Fig. 1B, Fig. 2). All identified correlations between BPRS subscale scores and structural measures remained significant in both the FEP and ARMS groups when controlling for medication status.

Discussion

In the present study we identified structural alterations in individuals with ARMS as a potential early endophenotype of psychosis. We observed extensive structural differences in both patients with FEP and those with ARMS as compared with healthy controls. Both the FEP and ARMS groups showed significantly faster age-related reductions in grey matter volume and VBCT than healthy controls in a largely overlapping anatomic network. We further found these structural alterations in patients with FEP and those with ARMS to be linked to the severity of psychotic symptoms.

In group comparisons of the ARMS and FEP groups with the control group we found increased grey matter volume in both patients with FEP and those with ARMS in a widespread anatomic set of regions covering predominantly left prefrontal, parietal, insular and temporal regions in patients with FEP and right parietal, prefrontal, insular and temporal regions in those with ARMS. Importantly, there were no significant differences between the FEP and ARMS groups.

Fig. 4: Voxel-based cortical thickness interaction analyses with age. (A) Regions showing significant age-related differences between individuals in an at-risk mental state (ARMS), patients with first-episode psychosis (FEP) and healthy controls are shown with the corresponding age plots for eigenvariates extracted from the most significant clusters provided in the top row. The outline colour of the plots corresponds to the colour of the significant clusters for the corresponding contrast. (B) Significant correlations in the FEP group between the Brief Psychiatric Rating Scale (BPRS) mood disturbance subcomponent and cortical thickness (cluster eigenvariates) in regions showing significant group × age interactions in the contrast control > ARMS (outlined in red) and control > FEP (outlined in blue).
In addition, the effect size of the structural alterations was similar for both the FEP and ARMS groups relative to the control group for all identified between-group differences. On one hand, these findings indicate that the structural alterations are indeed an early marker of psychosis already present in the ARMS population; on the other hand, the comparable magnitude of these alterations in both patients with FEP and those with ARMS indicates that these alterations are a stable endophenotype potentially predisposing to psychosis. In contrast, the magnitude of those alterations seems not to be linked to conversion from ARMS to FEP. However, this hypothesis remains to be tested in a proper longitudinal setting. In general, the findings of increased grey matter volume in parietal, insular, premotor and temporal regions in patients with schizophrenia and those with ARMS are consistent with previous reports and a recent meta-analysis of VBM studies suggesting an involvement of these regions in patients with schizophrenia and psychosis.5,46-52 However, the directionality of these grey matter volume abnormalities is discussed controversially in the literature.4,6,17,53 In fact, most studies, including our own, conducted in cohorts that did not overlap with the present one found grey matter volume decreases in these patient populations.5,54 A possible explanation for these differential findings across studies and meta-analyses with respect to direction of grey matter volume alterations in patients with psychosis could be due to the identified interactions between diagnosis and age in addition to previously reported treatment, genetic predisposition, ARMS duration or other confounding effects on grey matter structure.17,53,55-57 Among other reasons, including hardware and preprocessing differences, different definitions of the ARMS status could have contributed to the observed heterogeneity. Based on the criteria applied in our study we would, for example, expect our ARMS cohort to mainly comprise individuals with attenuated psychotic symptoms.58 Although the reasons for this divergence remain open, our findings question grey matter volume decreases as a common biomarker in FEP and ARMS populations, suggesting grey matter volume increases also exist in these patient cohorts. Regions showing interactions with age in our study cover an extensive anatomic network overlapping most of the regions also showing an increased grey matter volume in group comparisons. The identified interactions suggest an age-specific differential pattern of grey matter volume differences in these regions in both patients with FEP and those with ARMS compared with healthy controls. These differential findings need to be considered in future imaging studies in patients with schizophrenia and at-risk populations. Based on these findings, comparison of older patients with ARMS and FEP with healthy controls would likely result in more prevalent structural decreases. Similarly, use of 3T scanners compared with 1.5T scanners used in earlier studies along with novel preprocessing pipelines presumably improved segmentation of grey matter structures and may have increased sensitivity to detect grey matter tissue in patients with ARMS and those with FEP. Previous reports suggested, for example, selectively reduced density of oligodendroglia cells in layer VI of patients with schizophrenia.59 Such alterations at the grey and white matter boundary may lead to misleading shifts in classification of grey matter tissue.

In general, our findings of faster age-related grey matter volume reductions in patients with FEP and those with ARMS are in line with the findings of previous longitudinal studies and meta-analyses suggesting accelerated aging in patients with FEP and those with ARMS compared with healthy controls.6 Importantly, the interactions observed in our study are cross-sectional. Correspondingly, the observed age-dependent decreases in grey matter volume in both the FEP and ARMS groups cannot be directly attributed to disease progression, as it is possible that differential disease-related or compensational processes are associated with psychotic symptoms in younger and older patients with FEP and ARMS. The negative correlations we found between grey matter volume increases and symptom severity in patients with FEP suggest the assumption that compensational processes are linked to the grey matter volume increases in patients with FEP and those with ARMS. In contrast, the finding of a positive correlation between symptom severity and cortical thickness measures in regions of increased cortical thickness in individuals with ARMS support the assumption of disease-related contribution of these structural alterations. Interestingly, we found a gradient from anterior to posterior regions with respect to diagnosis x age interactions observed in grey matter volume. Although in this analysis the lateral prefrontal and premotor regions showed age-related grey matter volume reductions in both the FEP and ARMS groups, the more posterior motor and precuneal regions showed a stronger age-associated reduction only in the FEP group. With the limitation that these findings were obtained in a cross-sectional setting, they support the idea of abnormal nonlinear growth processes as a factor contributing to schizophrenia.60 However, they may also represent evidence of differential mechanisms underlying occurrence or the risk of psychosis in younger and older individuals. The observed negative correlation with the BPRS activation subcomponents comprising motor hyperactivity, excitement and distractibility items is supportive for involvement of grey matter volume abnormalities in these regions in psychotic symptoms. Though such cross-sectional correlations observed between clinical symptoms and brain structural phenotypes identified in patients with FEP and those with ARMS may indicate a dynamic link between brain plasticity in specific regions and the occurrence of respective clinical symptoms. Alternatively, they may also reflect a more static predisposition of patients with specific structural phenotypes for exhibiting more severe and specific clinical symptoms.

When comparing cortical thickness across groups we found bidirectional alterations in the ARMS cohort, with reduced cortical thickness in motor and premotor regions and increased cortical thickness in occipitoparietal areas. These findings of increased cortical thickness in individuals with ARMS are consistent with alterations observed in the FEP cohort and are positively correlated with symptom severity in individuals with ARMS, indicating their potential relevance for emergence of psychotic symptoms. Similar to grey matter volume, both decreases and increases were reported.
in previous studies evaluating cortical thickness in patients with schizophrenia or psychosis. Our findings suggest that both types of alterations coexist in patients with psychosis, indicating a more complex picture than just global cortical thinning as suggested in previous studies. Possible explanations for such bidirectional alterations could be a more complex neurodevelopmental imbalance of cortical development or potential compensatory effects across different brain regions. In individuals with ARMS we also found accelerated age-related decreases in cortical thickness in the default mode, theory of mind and working memory–associated regions. These findings are consistent with those of previous studies of longitudinal cortical thickness reductions in the development of psychosis. In patients with FEP, cortical thickness in these regions positively correlated with BPRS mood disturbance subcomponents, one of the key psychotic symptoms. Considering that none of the BPRS subcomponents correlated with age, these cross-sectional findings indicate that increased cortical thickness in these regions may be associated with increased risk of psychotic symptoms.

Limitations

The ARMS group comprised subgroups of individuals with different heterogeneous levels of psychosis risk, recruitment strategies and consecutive brain abnormalities. Furthermore, the cross-sectional nature of our study does not allow us to make direct conclusions about interactions with age being evidence of altered brain development. Though in line with this theory, our findings can also be interpreted as evidence of differential pathophysiological processes being linked to the emergence of psychotic symptoms in younger and older patients. The reduced number of older patients and controls is a further limitation of our study that might explain the slight age-related increase in grey matter volume and VBCT observed in healthy controls for some of the clusters. In that context, the lower number and the restrictive inclusion criteria for healthy controls (e.g., no family history of any psychiatric disorder) also may have led to biased findings with respect to identified structural alterations in both patient cohorts. As the slope of this increase is not significantly different from zero, these results are consistent with previous literature showing a relatively stable grey matter volume and VBCT in these mostly prefrontal regions in healthy controls for the age range evaluated in our study. Furthermore, both the FEP and ARMS groups included a significant number of individuals treated with antidepressants. Though in our correlational analyses we controlled for the potential effects of antidepressants or other medication on clinical symptoms, brain structure might have affected the group comparisons. Importantly, owing to the exploratory nature of the correlational analyses with clinical symptoms, we applied a more lenient statistical threshold. The respective findings should therefore be considered as hypothesis-generating and need to be validated in future studies. Finally, the FEP and ARMS groups had a higher proportion of male participants, and the ARMS group was slightly younger than the FEP and control groups. Both variables were included as control variables or variables of interest in the analyses to minimize their impact. Nonetheless, these differences and other uncontrolled factors, such as psychotic illness duration, subtypes of ARMS might have biased some of our findings.

Conclusion

The present findings of significantly faster age-related decline in grey matter volume and VBCT in the early phase of psychosis development that are linked to clinical symptoms have major implications for understanding the time of occurrence of these alterations. Interactions with age observed for these structural differences may explain the heterogeneity of current imaging findings during the early course of psychosis.

Affiliations: From the F. Hoffmann-La Roche, Pharma Research Early Development, Roche Innovation Centre Basel, Basel, Switzerland (Dukart); the Department of Psychiatry (UPK), University of Basel, Basel, Switzerland (Dukart, Smieskova, Lenz, Schmidt, Walter, Huber, Riecher-Rössler, Lang, Borgwardt); the University Hospital of Psychiatry, University Hospital of Bern, Bern, Switzerland, and Specialized Early Psychosis Outpatient Service for Adolescents and Young Adults, Department of Psychiatry, Bruderholz, Switzerland (Simon); and the Department of Psychiatry Studies, Institute of Psychiatry, Psychology and Neuroscience IoPPN, King’s College London, London, UK (Schmidt, Borgwardt).

Competing interests: J. Dukart is a full-time employee of F. Hoffmann-La Roche, but received no specific funding for this work. F. Hoffmann-La Roche provided support in the form of salary, but did not have any additional role in the study design, data collection, statistical analysis, decision to publish, or preparation of the manuscript.

Contributors: J. Dukart and S. Borgwardt designed the study. R. Smieskova, F. Harrisberger, C. Lenz, A. Schmidt, A. Walter and A. Simon acquired the data, which J. Dukart, C. Huber, A. Riecher-Rössler, U. Lang, P. Fusar-Poli and S. Borgwardt analyzed. J. Dukart wrote the article, which all authors reviewed and approved for publication.

References


44. Heaton RK, Gladsjo JA, Palmer BW, et al. Stability and course of neuropsychological deficits in schizophrenia. *Arch Gen Psychiatry* 2001;58:24-32.


